BTIG Maintains Buy on CareDx, Raises Price Target to $74

BTIG analyst Mark Massaro has reiterated a Buy rating on CareDx (NASDAQ: CDNA) and increased the price target from $60 to $74. This adjustment reflects a positive outlook for the company's performance in the market.